10-Q: Cell MedX Corp. Reports Q3 2024 Results, Completes Debt Conversion and Private Placement

Cell MedX Corp. released its Q3 2024 financial results, highlighting a significant debt conversion, a private placement, and changes in management.

Summary

• Cell MedX Corp. reported its financial results for the third quarter of fiscal year 2024, ending February 29, 2024.
• The company did not generate any revenue during the quarter, compared to $222 in the same period last year, due to the suspension of commercial activities following the loss of Health Canada licenses.
• Operating expenses decreased by 45.8% to $57,775 for the quarter, primarily due to a reduction in research and development costs.
• A significant debt settlement agreement was reached, converting $1,622,693 of debt into 231,813,310 shares of common stock at $0.007 per share.
• This debt conversion resulted in a gain on forgiveness of debt of $187,517.
• The company completed a private placement offering, raising $75,000 through the issuance of 2,500,000 units at $0.03 per unit.
• The company's net loss for the quarter was $119,971, compared to a net loss of $118,161 in the same quarter of the previous year.
• The company's accumulated deficit stands at $10,170,306 as of February 29, 2024.
• The company's working capital deficit is $709,946 as of February 29, 2024.
• The company's cash balance is $79,677 as of February 29, 2024.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including no revenue, a large accumulated deficit, and a going concern warning. While there are some positive developments like debt conversion and a private placement, the overall sentiment is negative due to the company's precarious financial situation.

Positives

• The company successfully reduced its debt through a significant debt conversion.
• The company raised additional capital through a private placement.
• Operating expenses were significantly reduced, primarily in research and development.
• The company recognized a gain on forgiveness of debt, improving its financial position.

Negatives

• The company generated no revenue during the quarter due to the suspension of commercial activities.
• The company continues to operate with a significant working capital deficit.
• The company has a substantial accumulated deficit.
• The company's cash balance remains low.

Risks

• The company's ability to continue as a going concern is uncertain due to its accumulated deficit and lack of revenue.
• The company is dependent on securing additional financing to meet its obligations.
• The company faces intense competition in the medical device and pharmaceutical industries.
• The company is subject to numerous governmental regulations, which can increase costs and delay product development.
• The company's intellectual property rights may not be adequately protected.
• The company's research and development efforts may not result in commercially successful products.
• The company may not be able to attract and retain key personnel.
• The company's stock is a penny stock, which limits shareholders' ability to sell their shares.

Future Outlook

The company plans to mitigate its shortfall in funds through equity or debt financing and is dependent on the continued financial support of its shareholders, its ability to obtain necessary debt or equity financing to continue operations, and the attainment of profitable operations.

Management Comments

• Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes, and/or private placement of common stock.
• Management is planning to mitigate the Company's shortfall in funds through equity or debt financing.

Industry Context

The company operates in the highly competitive biotech industry, facing competition from larger, well-established medical device and pharmaceutical companies. The company's focus on microcurrent technology for pain relief and diabetes management places it in a niche market with potential but also significant challenges.

Comparison to Industry Standards

• Cell MedX's lack of revenue and significant losses are not uncommon for early-stage biotech companies, especially those focused on novel technologies.
• Compared to established medical device companies like Medtronic or Johnson & Johnson, Cell MedX is significantly smaller and has limited resources.
• The company's reliance on related-party loans and debt conversions is a common practice for startups but also indicates a higher risk profile.
• The company's decision to suspend further development of the eBalance devices due to lack of funding is a common challenge for companies in this sector.
• The company's debt conversion and private placement are typical strategies for companies seeking to improve their financial position, but the success of these strategies depends on the company's ability to generate revenue and achieve profitability.

Management Changes

Corporate Governance

Related Party Transactions

• The company had significant transactions with related parties, including loans, management fees, and consulting fees.
• A company controlled by the former COO and current director assigned a total of $682,590 owed to it, with $425,590 transferred to the company's related parties.
• The company's former CEO assigned a total of $76,500 owed to him to Mr. Vahabzadeh.
• Mr. Richard Jeffs reassigned notes payable to Mr. David Jeffs.
• Mr. David Jeffs reassigned a portion of his debt to family members.
• Mr. Vahabzadeh acquired debt the company owed to one of its lenders.
• Mr. Ahdoot acquired debt the company owed to an entity controlled by the former COO and current director.
• The company entered into debt settlement agreements with related parties to convert debt into shares.
• Mr. Vahabzadeh and his spouse participated in the private placement offering.

Stakeholder Impact

• Shareholders experienced significant dilution due to the debt conversion.
• Shareholders face uncertainty due to the company's going concern issues.
• Employees may be affected by the company's financial difficulties.
• Creditors may be impacted by the company's debt restructuring.
• Customers are currently not impacted as the company has suspended commercial activities.

Next Steps

• The company needs to secure additional financing to continue operations.
• The company needs to develop a plan to generate revenue.
• The company needs to address its going concern issues.

Key Dates

Keywords

Cell MedX, debt conversion, private placement, financial results, biotech, eBalance Technology, microcurrent, medical devices, healthcare, going concern